New kit clarifies canine and feline lymphoma diagnosis

According to an announcement made at the Veterinary Cancer Society's annual conference, a company from the UK called PetScreen has developed a diagnostic kit that will take much of the uncertainty out of diagnosing lymphoma in dogs and cats.

The kit, known as the Advanced Lymphoma Blood Test (ALBT), has as its most significant attribute the ability to differentiate between animals with lymphadenopathy (enlarged lymph nodes) due to lymphoma and lymphadenopathy due to other health issues such as lymphoid hyperplasia.

It works by searching for levels of specific biomarkers in the blood, then applying an algorithm that measures those levels against other proteins in the blood to reach a conclusion.

The company also claims that results are returned the same day, making for quicker, more infiormed decision-making on the part of pet owners and veterinarians.

For more information , visit Pet-Screen.com

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap